Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of taltirelin tablets in spinocerebellar ataxia
CTR20250926Phase 3Active
- Sponsor
- Jiangsu Durui Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of taltirelin in spinocerebellar ataxia (SCA), sponsored by Jiangsu Durui Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
taltirelin
03
Conditions
spinocerebellar ataxia (SCA)
Beyond the preview
Go deeper on CTR20250926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250926.